Pivotal Global Phase III Study Data for Fycompa® (Perampanel) in Primary Generalised Tonic-Clonic Seizures Now Published in Neurology

HATFIELD, England, August 24, 2015 /PRNewswire/ --





PRESS RELEASE FOR EU MEDIA ONLY: NOT FOR AUSTRIA/SWISS/U.S. JOURNALISTS 

Newly published data evaluates the safety and efficacy of adjunctive perampanel for

idiopathic generalised epilepsy 

Pivotal, global phase III study results for Fycompa(R) (perampanel) in primary generalised tonic-clonic (PGTC) seizures are published for the first time today in Neurology.[1] Study 332 assesses the safety and efficacy of perampanel compared to placebo, in primary generalised tonic-clonic (PGTC) seizures in idiopathic generalised epilepsy (IGE). Perampanel, which received the new indication from the European Commission (EC) on 24 June 2015, is the first new treatment for PGTC seizures in five years.[2]

One third more patients treated with perampanel experience a 50% responder rate, which is statistically significant versus placebo (50% responder rate 64.2% vs 39.5%, respectively; P=0.0019).[1] Perampanel also demonstrates a reduction in PGTC seizure frequency (per 28 days) versus placebo (76.5% vs 38.4%, respectively; P

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234